官方服务：
资源简介：
Mean NRS-pruritus and DLQI evolution following upadacitinib 45mg intensification.
应用场景：
创建时间：
2025-12-25
相关数据集
Supplementary Material for: The Effects of Mucopolysaccharide Polysulfate on Steroid-Induced Tight Junction Barrier Dysfunction in Human Epidermal Keratinocytes and a 3D Skin Model
Introduction: The long-term use of topical corticosteroids (TCS) is associated with side effects such as skin atrophy and barrier deterioration. Moisturizers, such as mucopolysaccharide polysulfate (M
NIAID Data Ecosystem70
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial
Author video for the article: Paller AS, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, do
NIAID Data Ecosystem20
Long-Term Dupilumab Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis: A Real-World Single-Center Retrospective Study
This is the original drawing and notes of the pictures and tables supplemented in this article：Long-Term Dupilumab Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis: A Real-World Single-Cent
Mendeley Data20
Full-text articles assessed for eligibility.
Background The newly approved biologics and Janus kinase inhibitors (JAKi) for pediatric atopic dermatitis (AD) offer additional options for clinical treatment. However, the efficacy and safety differ
NIAID Data Ecosystem50
Supplementary Material for: Efficacy and Safety of Upadacitinib Versus Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Four Body Regions: Analysis From the Heads-Up Study
Introduction: Upadacitinib has demonstrated high and rapid rates of efficacy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) as assessed by the Eczema Area and Severity
Figshare2024-10-29 更新20
